\u4e0a\u6d772021\u5e741\u67086\u65e5 \/\u7f8e\u901a\u793e\/ — \u4e91\u9876\u65b0\u8000\uff08Everest Medicines\uff0cHKEX 1952.HK\uff09\uff0c\u4e00\u5bb6\u4e13\u6ce8\u4e8e\u521b\u65b0\u836f\u5f00\u53d1\u53ca\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\uff0c\u81f4\u529b\u4e8e\u6ee1\u8db3\u4e2d\u56fd\uff08\u542b\u9999\u6e2f\u3001\u6fb3\u95e8\u4ee5\u53ca\u53f0\u6e7e\u5730\u533a\uff09\u53ca\u4e9a\u6d32\u5176\u4ed6\u5e02\u573a\u672a\u88ab\u6ee1\u8db3\u7684\u533b\u7597\u9700\u6c42\uff0c\u4eca\u5929\u516c\u5e03\u65e5\u524d\u5df2\u5411\u65b0\u52a0\u5761\u536b\u751f\u79d1\u5b66\u5c40\u63d0\u4ea4\u4e86sacituzumab govitecan-hziy\u7528\u4e8e\u6cbb\u7597\u63a5\u53d7\u8fc7\u81f3\u5c11\u4e24\u7ebf\u65e2\u5f80\u6cbb\u7597\u7684\u8f6c\u79fb\u6027\u4e09\u9634\u6027\u4e73\u817a\u764c\u60a3\u8005\uff08\u4ee5\u4e0b\u7b80\u79f0mTNBC\uff09\u7684\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\u3002<\/p>\n
\u4e91\u9876\u65b0\u8000\u80bf\u7624\u9886\u57df\u9996\u5e2d\u533b\u5b66\u5b98\u65f6\u9633\u8868\u793a\uff0c\u201c\u5728\u65b0\u52a0\u5761\uff0c\u4e73\u817a\u764c\u662f\u5973\u6027\u56e0\u764c\u81f4\u6b7b\u7684\u4e3b\u8981<\/span>\u539f\u56e0\uff0c\u5176\u4e2d\u4e09\u9634\u6027\u4e73\u817a\u764c\u5360\u6240\u6709\u4e73\u817a\u764c\u7c7b\u578b\u768415%-20%\u3002\u6b64\u6b21\u7814\u53d1\u91cc\u7a0b\u7891\u6807\u5fd7\u7740\u4e91\u9876\u65b0\u8000\u9996\u6b21\u5728\u5176\u6388\u6743\u5f15\u8fdb\u7684\u5730\u533a\u63d0\u4ea4\u4e86sacituzumab govitecan-hziy\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\uff0c\u8fd9\u4e9b\u5730\u533a\u8fd8\u5c06\u5305\u62ec\u5927\u4e2d\u534e\u533a\u3001\u97e9\u56fd\u548c\u90e8\u5206\u5176\u4ed6\u4e1c\u5357\u4e9a\u56fd\u5bb6\/\u5730\u533a\u3002\u6211\u4eec\u671f\u5f85\u63a8\u8fdbsacituzumab govitecan-hziy\u5728\u65b0\u52a0\u5761\u83b7\u5f97\u6279\u51c6\uff0c\u540c\u65f6\u5728\u4ee5\u4e0a\u5176\u4ed6\u533a\u57df\u63a8\u52a8\u4e34\u5e8a\u7814\u53d1\u548c\u6ce8\u518c\u9879\u76ee\u7684\u8fdb\u5c55\uff0c\u4e3a\u65b0\u5174\u4e9a\u592a\u5e02\u573a\u7f79\u60a3\u8be5\u6076\u6027\u75be\u75c5\u7684\u60a3\u8005\u5e26\u6765\u8fd9\u4e00\u521b\u65b0\u578b\u6cbb\u7597\u3002\u201d<\/p>\n \u4e91\u9876\u65b0\u8000\u9996\u5e2d\u6267\u884c\u5b98\u3001\u533b\u5b66\u535a\u58eb\u8584\u79d1\u745e\u8868\u793a\uff1a\u201c\u6211\u4eec\u5bf9\u5b8c\u6210\u6b64\u6b21\u7533\u8bf7\u611f\u5230\u632f\u594b\uff0c\u5b83\u4e3a\u4e91\u9876\u65b0\u8000\u5728\u4e2d\u56fd\u3001\u4ee5\u53ca\u56fd\u9645\u5e02\u573a\u6253\u9020\u5f3a\u52b2\u5546\u4e1a\u5f62\u8c61\u7684\u5e7f\u9614\u5546\u4e1a\u6218\u7565\u63d0\u4f9b\u4e86\u652f\u6301\u3002\u540c\u65f6\uff0c\u6211\u4eec\u59cb\u7ec8\u81f4\u529b\u4e8e\u4e3a\u4e9a\u592a\u5730\u533a\u60a3\u8005\u63d0\u4f9b\u548c\u52a0\u5feb\u5168\u7403\u533b\u836f\u521b\u65b0\u7597\u6cd5\u800c\u52aa\u529b\u3002\u201d<\/p>\n \u5173\u4e8e<\/b> Sacituzumab Govitecan-Hziy<\/b><\/p>\n Sacituzumab govitecan-hziy \u662f\u4e00\u6b3e\u540c\u7c7b\u9886\u5148<\/span>\u7684\u6297\u4f53\u836f\u7269\u5076\u8054\u7269\uff0c\u9776\u70b9\u4e3aTROP-2\uff0c\u5176\u4e3a\u5728\u8bb8\u591a\u5e38\u89c1\u7684\u4e0a\u76ae\u764c\u4e2d\u6709\u8fc7\u5ea6\u8868\u8fbe\u7684\u819c\u6297\u539f\u3002Sacituzumab govitecan-hziy\u4e8e2020\u5e744\u6708\u83b7\u5f97\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u7ba1\u7406\u5c40\u7684\u52a0\u901f\u5ba1\u6279\u7528\u4e8e\u6cbb\u7597\u5df2\u63a5\u53d7\u8fc7\u81f3\u5c11\u4e24\u7ebf\u65e2\u5f80\u9488\u5bf9\u8f6c\u79fb\u6027\u75be\u75c5\u6cbb\u7597\u7684mTNBC\u60a3\u8005\u3002\u6839\u636e\u5173\u952e\u60273\u671fASCENT\u4e34\u5e8a\u8bd5\u9a8c\u7684\u6570\u636e\uff0c\u4e0e\u6807\u51c6\u5316\u7597\u76f8\u6bd4\uff0c\u4f7f\u7528sacituzumab govitecan-hziy\u6cbb\u7597\u53ef\u5c06\u6b7b\u4ea1\u98ce\u9669\u964d\u4f4e52%\uff08p <0.0001\uff09\uff0c\u5c06\u75be\u75c5\u8fdb\u5c55\u98ce\u9669\u964d\u4f4e59%\uff08p <0.0001\uff09\uff0c\u5e76\u63d0\u9ad8\u4e2d\u4f4d\u603b\u751f\u5b58\u671f\uff0812.1 vs. 6.7\u6708\uff09\u3002\u4f9d\u636e\u4e0e\u5409\u5229\u5fb7\u79d1\u5b66\u516c\u53f8\u7b7e\u7f72\u7684\u6388\u6743\u5f15\u8fdb\u534f\u8bae\uff0c\u4e91\u9876\u65b0\u8000\u62e5\u6709sacituzumab govitecan-hziy\u5728\u5927\u4e2d\u534e\u533a\u3001\u97e9\u56fd\u548c\u90e8\u5206\u4e1c\u5357\u4e9a\u56fd\u5bb6\u7684\u7814\u53d1\u3001\u6ce8\u518c\u548c\u5546\u4e1a\u5316\u7684\u6743\u5229\u3002<\/p>\n Sacituzumab govitecan-hziy\u5df2\u4e8e2020\u5e7410\u6708\u88ab\u7eb3\u5165\u6700\u65b0\u66f4\u65b0\u76842020\u7248\u300a\u4e2d\u56fd\u665a\u671f\u4e73\u817a\u764c\u89c4\u8303\u8bca\u7597\u6307\u5357\u300b\uff0c\u8be5\u6307\u5357\u7531\u4e2d\u56fd\u7684\u56fd\u5bb6\u80bf\u7624\u8d28\u63a7\u4e2d\u5fc3\u4e73\u817a\u764c\u4e13\u5bb6\u59d4\u5458\u4f1a\u3001\u4e2d\u56fd\u6297\u764c\u534f\u4f1a\u4e73\u817a\u764c\u4e13\u4e1a\u59d4\u5458\u4f1a\u3001\u4e2d\u56fd\u6297\u764c\u534f\u4f1a\u80bf\u7624\u836f\u7269\u4e34\u5e8a\u7814\u7a76\u4e13\u4e1a\u59d4\u5458\u4f1a\u5171\u540c\u7f16\u64b0\u3002<\/p>\n \u5173\u4e8e\u4e09\u9634\u6027\u4e73\u817a\u764c<\/b><\/p>\n \u4e09\u9634\u6027\u4e73\u817a\u764c\u662f\u4e00\u79cd\u9ad8\u5ea6\u4fb5\u88ad\u6027\u75be\u75c5\uff0c\u7ea6\u5360\u5168\u7403\u6240\u6709\u4e73\u817a\u764c\u7c7b\u578b\u768415%-20%i-iii<\/sup>\u3002\u4e2d\u56fd\u4e73\u817a\u764c\u7684\u8bca\u65ad\u5e74\u9f84\u4e2d\u4f4d\u6570\u4e0e\u897f\u65b9\u56fd\u5bb6\u76f8\u6bd4\u6709\u5e74\u8f7b\u5316\u8d8b\u52bf\uff0c\u8fd110\u5e74\u6765\uff0c\u4e09\u9634\u6027\u4e73\u817a\u764c\u5206\u5b50\u4e9a\u578b\u7684\u6bd4\u4f8b\u9010\u6b65\u4e0a\u5347\u3002\u4e09\u9634\u6027\u4e73\u817a\u764c\u80bf\u7624\u7f3a\u4e4f\u8db3\u591f\u7684\u96cc\u6fc0\u7d20\u3001\u5b55\u6fc0\u7d20\u6216HER2\u53d7\u4f53\u8868\u8fbe, \u5185\u5206\u6ccc\u7597\u6cd5\u6216HER2\u9776\u5411\u6cbb\u7597\u57fa\u672c\u65e0\u6548\u3002\u5728\u8fc7\u53bb20\u591a\u5e74\u4e2d\uff0c\u4e09\u9634\u4e73\u817a\u764c\u60a3\u8005\u7684\u603b\u751f\u5b58\u671f\u6ca1\u6709\u6539\u5584\uff0c\u56e0\u6b64\u4e9f\u9700\u5f00\u53d1\u65b0\u7684\u6709\u6548\u6cbb\u7597\u65b9\u6848iv-viii<\/sup>\u3002<\/p>\n \u5173\u4e8e\u4e91\u9876\u65b0\u8000<\/b><\/p>\n \u4e91\u9876\u65b0\u8000\u662f\u4e00\u5bb6\u4e13\u6ce8\u4e8e\u521b\u65b0\u836f\u5f00\u53d1\u53ca\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\uff0c\u81f4\u529b\u4e8e\u6ee1\u8db3\u5927\u4e2d\u534e\u533a\u53ca\u5176\u5b83\u4e9a\u6d32\u5e02\u573a\u672a\u6ee1\u8db3\u7684\u533b\u7597\u9700\u6c42\u3002\u4e91\u9876\u65b0\u8000\u7684\u7ba1\u7406\u56e2\u961f\u5728\u56fd\u5185\u5916\u9ad8\u8d28\u91cf\u4e34\u5e8a\u5f00\u53d1\u3001\u836f\u653f\u4e8b\u52a1\u3001\u5316\u5b66\u5236\u9020\u4e0e\u63a7\u5236(CMC)\u3001\u4e1a\u52a1\u53d1\u5c55\u548c\u8fd0\u8425\u65b9\u9762\u62e5\u6709\u6df1\u539a\u7684\u4e13\u957f\u548c\u4e30\u5bcc\u7684\u7ecf\u9a8c\u3002\u4e91\u9876\u65b0\u8000\u5df2\u6253\u9020\u4e868\u6b3e\u6709\u6f5c\u529b\u6210\u4e3a\u5168\u7403\u540c\u7c7b\u9996\u521b\u6216\u8005\u540c\u7c7b\u6700\u4f73\u7684\u836f\u7269\u7ec4\u5408\uff0c\u5176\u4e2d\u5927\u90e8\u5206\u5df2\u7ecf\u5904\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u540e\u671f\u9636\u6bb5\u3002\u516c\u53f8\u7684\u6cbb\u7597\u9886\u57df\u5305\u62ec\u80bf\u7624\u3001\u81ea\u4f53\u514d\u75ab\u6027\u75be\u75c5\u3001\u5fc3\u80be\u75be\u75c5\u548c\u611f\u67d3\u6027\u75be\u75c5\u3002\u6b32\u77e5\u8be6\u7ec6\u4fe1\u606f\uff0c\u8bf7\u8bbf\u95ee\u516c\u53f8\u7f51\u7ad9\uff1awww.everestmedicines.com<\/a>\u3002<\/span><\/p>\n \u66f4\u591a\u4fe1\u606f\uff0c\u656c\u8bf7\u5782\u8be2\uff1a<\/b><\/p>\n Everest Medicines Media in China<\/span>: i. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin 2016;66:31-42. \u76f8\u5173\u94fe\u63a5 :<\/p>\n http:\/\/www.everestmedicines.com<\/p>\n","protected":false},"excerpt":{"rendered":" \u4e0a\u6d772021\u5e741\u67086\u65e5 \/\u7f8e\u901a\u793e\/ — \u4e91\u9876\u65b0\u8000\uff08Everest Medicines\uff0cHKEX 1952.HK\uff09\uff0c\u4e00\u5bb6\u4e13\u6ce8\u4e8e\u521b\u65b0\u836f\u5f00\u53d1\u53ca\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\uff0c\u81f4\u529b\u4e8e\u6ee1\u8db3\u4e2d\u56fd\uff08\u542b\u9999\u6e2f\u3001\u6fb3\u95e8\u4ee5\u53ca\u53f0\u6e7e\u5730\u533a\uff09\u53ca\u4e9a\u6d32\u5176\u4ed6\u5e02\u573a\u672a\u88ab\u6ee1\u8db3\u7684\u533b\u7597\u9700\u6c42\uff0c\u4eca\u5929\u516c\u5e03\u65e5\u524d\u5df2\u5411\u65b0\u52a0\u5761\u536b\u751f\u79d1\u5b66\u5c40\u63d0\u4ea4\u4e86sacituzumab govitecan-hziy\u7528\u4e8e\u6cbb\u7597\u63a5\u53d7\u8fc7\u81f3\u5c11\u4e24\u7ebf\u65e2\u5f80\u6cbb\u7597\u7684\u8f6c\u79fb\u6027\u4e09\u9634\u6027\u4e73\u817a\u764c\u60a3\u8005\uff08\u4ee5\u4e0b\u7b80\u79f0mTNBC\uff09\u7684\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\u3002 \u4e91\u9876\u65b0\u8000\u80bf\u7624\u9886\u57df\u9996\u5e2d\u533b\u5b66\u5b98\u65f6\u9633\u8868\u793a\uff0c\u201c\u5728\u65b0\u52a0\u5761\uff0c\u4e73\u817a\u764c\u662f\u5973\u6027\u56e0\u764c\u81f4\u6b7b\u7684\u4e3b\u8981\u539f\u56e0\uff0c\u5176\u4e2d\u4e09\u9634\u6027\u4e73\u817a\u764c\u5360\u6240\u6709\u4e73\u817a\u764c\u7c7b\u578b\u768415%-20%\u3002\u6b64\u6b21\u7814\u53d1\u91cc\u7a0b\u7891\u6807\u5fd7\u7740\u4e91\u9876\u65b0\u8000\u9996\u6b21\u5728\u5176\u6388\u6743\u5f15\u8fdb\u7684\u5730\u533a\u63d0\u4ea4\u4e86sacituzumab govitecan-hziy\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\uff0c\u8fd9\u4e9b\u5730\u533a\u8fd8\u5c06\u5305\u62ec\u5927\u4e2d\u534e\u533a\u3001\u97e9\u56fd\u548c\u90e8\u5206\u5176\u4ed6\u4e1c\u5357\u4e9a\u56fd\u5bb6\/\u5730\u533a\u3002\u6211\u4eec\u671f\u5f85\u63a8\u8fdbsacituzumab govitecan-hziy\u5728\u65b0\u52a0\u5761\u83b7\u5f97\u6279\u51c6\uff0c\u540c\u65f6\u5728\u4ee5\u4e0a\u5176\u4ed6\u533a\u57df\u63a8\u52a8\u4e34\u5e8a\u7814\u53d1\u548c\u6ce8\u518c\u9879\u76ee\u7684\u8fdb\u5c55\uff0c\u4e3a\u65b0\u5174\u4e9a\u592a\u5e02\u573a\u7f79\u60a3\u8be5\u6076\u6027\u75be\u75c5\u7684\u60a3\u8005\u5e26\u6765\u8fd9\u4e00\u521b\u65b0\u578b\u6cbb\u7597\u3002\u201d \u4e91\u9876\u65b0\u8000\u9996\u5e2d\u6267\u884c\u5b98\u3001\u533b\u5b66\u535a\u58eb\u8584\u79d1\u745e\u8868\u793a\uff1a\u201c\u6211\u4eec\u5bf9\u5b8c\u6210\u6b64\u6b21\u7533\u8bf7\u611f\u5230\u632f\u594b\uff0c\u5b83\u4e3a\u4e91\u9876\u65b0\u8000\u5728\u4e2d\u56fd\u3001\u4ee5\u53ca\u56fd\u9645\u5e02\u573a\u6253\u9020\u5f3a\u52b2\u5546\u4e1a\u5f62\u8c61\u7684\u5e7f\u9614\u5546\u4e1a\u6218\u7565\u63d0\u4f9b\u4e86\u652f\u6301\u3002\u540c\u65f6\uff0c\u6211\u4eec\u59cb\u7ec8\u81f4\u529b\u4e8e\u4e3a\u4e9a\u592a\u5730\u533a\u60a3\u8005\u63d0\u4f9b\u548c\u52a0\u5feb\u5168\u7403\u533b\u836f\u521b\u65b0\u7597\u6cd5\u800c\u52aa\u529b\u3002\u201d \u5173\u4e8e Sacituzumab Govitecan-Hziy Sacituzumab govitecan-hziy \u662f\u4e00\u6b3e\u540c\u7c7b\u9886\u5148\u7684\u6297\u4f53\u836f\u7269\u5076\u8054\u7269\uff0c\u9776\u70b9\u4e3aTROP-2\uff0c\u5176\u4e3a\u5728\u8bb8\u591a\u5e38\u89c1\u7684\u4e0a\u76ae\u764c\u4e2d\u6709\u8fc7\u5ea6\u8868\u8fbe\u7684\u819c\u6297\u539f\u3002Sacituzumab govitecan-hziy\u4e8e2020\u5e744\u6708\u83b7\u5f97\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u7ba1\u7406\u5c40\u7684\u52a0\u901f\u5ba1\u6279\u7528\u4e8e\u6cbb\u7597\u5df2\u63a5\u53d7\u8fc7\u81f3\u5c11\u4e24\u7ebf\u65e2\u5f80\u9488\u5bf9\u8f6c\u79fb\u6027\u75be\u75c5\u6cbb\u7597\u7684mTNBC\u60a3\u8005\u3002\u6839\u636e\u5173\u952e\u60273\u671fASCENT\u4e34\u5e8a\u8bd5\u9a8c\u7684\u6570\u636e\uff0c\u4e0e\u6807\u51c6\u5316\u7597\u76f8\u6bd4\uff0c\u4f7f\u7528sacituzumab govitecan-hziy\u6cbb\u7597\u53ef\u5c06\u6b7b\u4ea1\u98ce\u9669\u964d\u4f4e52%\uff08p <0.0001\uff09\uff0c\u5c06\u75be\u75c5\u8fdb\u5c55\u98ce\u9669\u964d\u4f4e59%\uff08p <0.0001\uff09\uff0c\u5e76\u63d0\u9ad8\u4e2d\u4f4d\u603b\u751f\u5b58\u671f\uff0812.1 vs. 6.7\u6708\uff09\u3002\u4f9d\u636e\u4e0e\u5409\u5229\u5fb7\u79d1\u5b66\u516c\u53f8\u7b7e\u7f72\u7684\u6388\u6743\u5f15\u8fdb\u534f\u8bae\uff0c\u4e91\u9876\u65b0\u8000\u62e5\u6709sacituzumab govitecan-hziy\u5728\u5927\u4e2d\u534e\u533a\u3001\u97e9\u56fd\u548c\u90e8\u5206\u4e1c\u5357\u4e9a\u56fd\u5bb6\u7684\u7814\u53d1\u3001\u6ce8\u518c\u548c\u5546\u4e1a\u5316\u7684\u6743\u5229\u3002 Sacituzumab govitecan-hziy\u5df2\u4e8e2020\u5e7410\u6708\u88ab\u7eb3\u5165\u6700\u65b0\u66f4\u65b0\u76842020\u7248\u300a\u4e2d\u56fd\u665a\u671f\u4e73\u817a\u764c\u89c4\u8303\u8bca\u7597\u6307\u5357\u300b\uff0c\u8be5\u6307\u5357\u7531\u4e2d\u56fd\u7684\u56fd\u5bb6\u80bf\u7624\u8d28\u63a7\u4e2d\u5fc3\u4e73\u817a\u764c\u4e13\u5bb6\u59d4\u5458\u4f1a\u3001\u4e2d\u56fd\u6297\u764c\u534f\u4f1a\u4e73\u817a\u764c\u4e13\u4e1a\u59d4\u5458\u4f1a\u3001\u4e2d\u56fd\u6297\u764c\u534f\u4f1a\u80bf\u7624\u836f\u7269\u4e34\u5e8a\u7814\u7a76\u4e13\u4e1a\u59d4\u5458\u4f1a\u5171\u540c\u7f16\u64b0\u3002 \u5173\u4e8e\u4e09\u9634\u6027\u4e73\u817a\u764c \u4e09\u9634\u6027\u4e73\u817a\u764c\u662f\u4e00\u79cd\u9ad8\u5ea6\u4fb5\u88ad\u6027\u75be\u75c5\uff0c\u7ea6\u5360\u5168\u7403\u6240\u6709\u4e73\u817a\u764c\u7c7b\u578b\u768415%-20%i-iii\u3002\u4e2d\u56fd\u4e73\u817a\u764c\u7684\u8bca\u65ad\u5e74\u9f84\u4e2d\u4f4d\u6570\u4e0e\u897f\u65b9\u56fd\u5bb6\u76f8\u6bd4\u6709\u5e74\u8f7b\u5316\u8d8b\u52bf\uff0c\u8fd110\u5e74\u6765\uff0c\u4e09\u9634\u6027\u4e73\u817a\u764c\u5206\u5b50\u4e9a\u578b\u7684\u6bd4\u4f8b\u9010\u6b65\u4e0a\u5347\u3002\u4e09\u9634\u6027\u4e73\u817a\u764c\u80bf\u7624\u7f3a\u4e4f\u8db3\u591f\u7684\u96cc\u6fc0\u7d20\u3001\u5b55\u6fc0\u7d20\u6216HER2\u53d7\u4f53\u8868\u8fbe, \u5185\u5206\u6ccc\u7597\u6cd5\u6216HER2\u9776\u5411\u6cbb\u7597\u57fa\u672c\u65e0\u6548\u3002\u5728\u8fc7\u53bb20\u591a\u5e74\u4e2d\uff0c\u4e09\u9634\u4e73\u817a\u764c\u60a3\u8005\u7684\u603b\u751f\u5b58\u671f\u6ca1\u6709\u6539\u5584\uff0c\u56e0\u6b64\u4e9f\u9700\u5f00\u53d1\u65b0\u7684\u6709\u6548\u6cbb\u7597\u65b9\u6848iv-viii\u3002 \u5173\u4e8e\u4e91\u9876\u65b0\u8000 \u4e91\u9876\u65b0\u8000\u662f\u4e00\u5bb6\u4e13\u6ce8\u4e8e\u521b\u65b0\u836f\u5f00\u53d1\u53ca\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\uff0c\u81f4\u529b\u4e8e\u6ee1\u8db3\u5927\u4e2d\u534e\u533a\u53ca\u5176\u5b83\u4e9a\u6d32\u5e02\u573a\u672a\u6ee1\u8db3\u7684\u533b\u7597\u9700\u6c42\u3002\u4e91\u9876\u65b0\u8000\u7684\u7ba1\u7406\u56e2\u961f\u5728\u56fd\u5185\u5916\u9ad8\u8d28\u91cf\u4e34\u5e8a\u5f00\u53d1\u3001\u836f\u653f\u4e8b\u52a1\u3001\u5316\u5b66\u5236\u9020\u4e0e\u63a7\u5236(CMC)\u3001\u4e1a\u52a1\u53d1\u5c55\u548c\u8fd0\u8425\u65b9\u9762\u62e5\u6709\u6df1\u539a\u7684\u4e13\u957f\u548c\u4e30\u5bcc\u7684\u7ecf\u9a8c\u3002\u4e91\u9876\u65b0\u8000\u5df2\u6253\u9020\u4e868\u6b3e\u6709\u6f5c\u529b\u6210\u4e3a\u5168\u7403\u540c\u7c7b\u9996\u521b\u6216\u8005\u540c\u7c7b\u6700\u4f73\u7684\u836f\u7269\u7ec4\u5408\uff0c\u5176\u4e2d\u5927\u90e8\u5206\u5df2\u7ecf\u5904\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u540e\u671f\u9636\u6bb5\u3002\u516c\u53f8\u7684\u6cbb\u7597\u9886\u57df\u5305\u62ec\u80bf\u7624\u3001\u81ea\u4f53\u514d\u75ab\u6027\u75be\u75c5\u3001\u5fc3\u80be\u75be\u75c5\u548c\u611f\u67d3\u6027\u75be\u75c5\u3002\u6b32\u77e5\u8be6\u7ec6\u4fe1\u606f\uff0c\u8bf7\u8bbf\u95ee\u516c\u53f8\u7f51\u7ad9\uff1awww.everestmedicines.com\u3002 \u66f4\u591a\u4fe1\u606f\uff0c\u656c\u8bf7\u5782\u8be2\uff1a Everest MedicinesMedia in US and Europe:Darcie RobinsonVice PresidentWestwicke PR(203) 919-7905darcie.robinson@icrinc.com Media in China:Edmond LococoManaging DirectorICR Asia+86 (10) 6583-7510edmond.lococo@icrinc.com i. DeSantis CE, Fedewa SA, Goding… Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":8278,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-16786","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/16786","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=16786"}],"version-history":[{"count":1,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/16786\/revisions"}],"predecessor-version":[{"id":16787,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/16786\/revisions\/16787"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/8278"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=16786"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=16786"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=16786"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Media in US and Europe<\/span>:
Darcie Robinson<\/span>
Vice President
Westwicke PR
(203) 919-7905
darcie.robinson@icrinc.com<\/a> <\/p>\n
Edmond Lococo<\/span>
Managing Director
ICR Asia
+86 (10) 6583-7510
edmond.lococo@icrinc.com<\/a> <\/p>\n
<\/i>ii. 4. Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR. Features of triple-negative breast cancer: analysis of 38,813 cases from the National Cancer Database. Medicine (Baltimore<\/span>) 2016;95(35):e4614.
<\/i>iii. Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race\/ ethnicity, poverty, and state. J Natl Cancer Inst 2015;107(6):djv048.
<\/i>iv. Khosravi-Shahi P, Cabezon-Gutierrez L, Custodio-Cabello S<\/span>. Metastatic triple negative breast cancer: optimizing treatment options, new and emerging targeted therapies. Asia Pac J Clin Oncol 2018;14: 32-9.
<\/i>v. Brufsky A, Valero V, Tiangco B, et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat 2012;133: 1067-75.
<\/i>vi. Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER\/PR\/HER2- negative (triple-negative) breast cancer. Breast Cancer Res Treat 2010;121:261-71.
<\/i>vii. Park IH, Im SA, Jung KH, et al. Randomized open label phase III trial of irinotecan plus capecitabine versus capecitabine monotherapy in patients with metastatic breast cancer previously treated with anthracycline and taxane: PROCEED trial (KCSG BR 11-01). Cancer Res Treat 2019; 51:43-52.
<\/i>viii. Twelves C, Awada A, Cortes J, et al. Subgroup analyses from a phase 3, openlabel, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer (Auckl) 2016;10:77- 84.<\/i><\/p>\n